Akebia Therapeutics Inc (AKBA) financials
Akebia Therapeutics revenue and earnings by year
Akebia Therapeutics's revenue was $236 million in the fiscal year to December 31, 2025, up 47.5% from the year before. Net income was -$5.34 million, -2.3% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 75.0% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 236 | 160 | 195 | 292 | 212 | 295 | 335 | 208 | 181 | 2 |
| Revenue growth | 47.5% | -17.7% | -33.5% | 38.2% | -28.2% | -12.0% | 61.3% | 14.6% | 11706.3% | — |
| Gross profit | 197 | 97 | 120 | 207 | 61 | -2 | 190 | 200 | — | — |
| Gross margin | 83.3% | 60.6% | 61.9% | 70.7% | 28.8% | -0.6% | 56.6% | 96.3% | — | — |
| Operating income | 27 | -47 | -43 | -78 | -265 | -378 | -286 | -178 | -77 | -136 |
| Operating margin | 11.4% | -29.5% | -22.1% | -26.5% | -125.0% | -128.2% | -85.5% | -85.8% | -42.3% | -8889.9% |
| Net income | -5 | -69 | -52 | -94 | -282 | -385 | -280 | -144 | -74 | -136 |
| Net margin | -2.3% | -43.3% | -26.7% | -32.2% | -133.3% | -130.6% | -83.5% | -69.1% | -40.7% | -8843.5% |
| Diluted EPS | -$0.02 | -$0.33 | -$0.28 | -$0.52 | -$1.70 | — | — | — | -$1.86 | — |
| Free cash flow | 68 | -41 | -23 | -73 | -253 | -111 | -264 | -99 | -58 | 55 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open AKBA in Markets.
How Akebia Therapeutics makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Auryxia | $25.5M | 51.8% |
| Vafseo | $21.3M | 43.4% |
| License Collaboration & Other Revenue | $2.36M | 4.8% |
See also: AKBA returns
No forecast, no recommendation. This page describes Akebia Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.